Cue Biopharma (NASDAQ:CUE) Issues Quarterly Earnings Results

Cue Biopharma (NASDAQ:CUE) released its earnings results on Monday. The company reported $0.01 earnings per share for the quarter, FiscalAI reports. The company had revenue of $21.94 million for the quarter. Cue Biopharma had a negative return on equity of 271.67% and a negative net margin of 530.75%.

Cue Biopharma Stock Performance

Shares of NASDAQ CUE opened at $0.31 on Tuesday. The firm’s fifty day moving average is $0.32 and its two-hundred day moving average is $0.52. Cue Biopharma has a 52-week low of $0.23 and a 52-week high of $1.05. The company has a market cap of $24.53 million, a P/E ratio of -0.68 and a beta of 1.52. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.66 and a current ratio of 1.66.

Institutional Investors Weigh In On Cue Biopharma

Several large investors have recently made changes to their positions in CUE. GC Wealth Management RIA LLC lifted its position in shares of Cue Biopharma by 35.0% in the fourth quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company’s stock worth $1,415,000 after buying an additional 1,200,000 shares in the last quarter. Boothbay Fund Management LLC bought a new position in Cue Biopharma during the third quarter valued at approximately $439,000. Texas Capital Bank Wealth Management Services Inc grew its holdings in Cue Biopharma by 1,231.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after buying an additional 407,568 shares in the last quarter. Squarepoint Ops LLC bought a new stake in Cue Biopharma in the 3rd quarter worth approximately $62,000. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Cue Biopharma by 730.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after acquiring an additional 73,000 shares during the last quarter. 35.04% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cue Biopharma in a report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cue Biopharma currently has a consensus rating of “Sell”.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.